Neogenomics: Solid Fundamentals, Yet a Case of Overvaluation – A Delightfully Offbeat Take
NeoGenomics: A Promising Player in the Cancer Genomics Industry with Challenges NeoGenomics, Inc. (NGM), a leading provider of cancer-focused genetic testing services, has recently experienced a significant stock price drop following its Q3 2022 earnings report. The company was rated as a “Hold” by analysts due to its intrinsic value being lower than the current…